A prospective study to compare immediate with deferred treatment in advanced, localised and asymptomatic metastatic newly diagnosed prostatic carcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN14557194

Enrollment

938

Registered

2002-08-19

Start date

2000-08-01

Completion date

Unknown

Last updated

2019-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer Cancer

Interventions

1. Immediate Group: Total or subcapsular orchidectomy or administration of a Lutenizing Hormone Releasing Hormone (LHRH) analogue. Suggested LHRH analogues are goserelin acetate (Zoladex) 3.6 mg month

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1. Histologically proven adenocarcinoma of the prostate 2. Stage T2-T4 M0 or T1-T4 M1 (provided metastases are asymptomatic) 3. World Health Organisation (WHO) performance status 0-2 4. Life expectancy of >1 year 5. No previous or coexisting non prostatic malignancy except basal cell carcinoma 6. No previous treatment for prostatic carcinoma other than transurethral resection (TUR) 7. Patients in whom a deferred policy is inappropriate should not be entered into this study

Exclusion criteria

Exclusion criteria: Not provided at time of registration.

Design outcomes

Primary

Measure	Time frame
Not provided at time of registration.	—

Secondary

Measure	Time frame
Not provided at time of registration.	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026